Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Background Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to immune checkpoint blockade, owing to its ...
In a recent update, the National Comprehensive Cancer Network (NCCN) recommended capivasertib combined with fulvestrant for hormone receptor–positive and HER2-negative locally advanced or metastatic ...
Nicotinamide adenine dinucleotide (NAD) and its reduced form (NADH) therapy are dietary supplements that are promoted widely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results